Centessa Pharmaceuticals PLC
CNTA23.490USD
-0.050-0.21%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
3.16BMarket Cap
LossP/E TTM
More Details of Centessa Pharmaceuticals PLC Company
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
Centessa Pharmaceuticals PLC Info
Ticker SymbolCNTA
Company nameCentessa Pharmaceuticals PLC
IPO dateMay 28, 2021
CEOSaha (Saurabh)
Number of employees77
Security typeDepository Receipt
Fiscal year-endMay 28
Address3rd Floor
CityALTRINCHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeWA14 2DT
Phone447391789784
Websitehttps://www.centessa.com/
Ticker SymbolCNTA
IPO dateMay 28, 2021
CEOSaha (Saurabh)
Company Executives of Centessa Pharmaceuticals PLC
Name
Name/Position
Position
Shareholding
Change
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
77.08K
+16842.00%
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
45.17K
--
Mr. Iqbal Hussain
Mr. Iqbal Hussain
General Counsel and Chief Compliance Officer, Company Secretary
General Counsel and Chief Compliance Officer, Company Secretary
--
--
Ms. Tia Bush
Ms. Tia Bush
Chief Technology and Quality Officer
Chief Technology and Quality Officer
--
--
Dr. Francesco de Rubertis, Ph.D.
Dr. Francesco de Rubertis, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Arjun Goyal, M.D.
Dr. Arjun Goyal, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Brett I. W. Zbar, M.D.
Dr. Brett I. W. Zbar, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mary Lynne Hedley, Ph.D.
Dr. Mary Lynne Hedley, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Carol Stuckley
Ms. Carol Stuckley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
77.08K
+16842.00%
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
45.17K
--
Mr. Iqbal Hussain
Mr. Iqbal Hussain
General Counsel and Chief Compliance Officer, Company Secretary
General Counsel and Chief Compliance Officer, Company Secretary
--
--
Ms. Tia Bush
Ms. Tia Bush
Chief Technology and Quality Officer
Chief Technology and Quality Officer
--
--
Dr. Francesco de Rubertis, Ph.D.
Dr. Francesco de Rubertis, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Arjun Goyal, M.D.
Dr. Arjun Goyal, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Jan 18
Updated: Sun, Jan 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Medicxi Ventures (UK) LLP
13.67%
Avoro Capital Advisors LLC
7.40%
Adage Capital Management, L.P.
6.87%
Index Ventures SA
6.82%
General Atlantic LLC
5.04%
Other
60.19%
Shareholders
Shareholders
Proportion
Medicxi Ventures (UK) LLP
13.67%
Avoro Capital Advisors LLC
7.40%
Adage Capital Management, L.P.
6.87%
Index Ventures SA
6.82%
General Atlantic LLC
5.04%
Other
60.19%
Shareholder Types
Shareholders
Proportion
Venture Capital
21.32%
Investment Advisor/Hedge Fund
20.31%
Hedge Fund
19.37%
Investment Advisor
16.87%
Private Equity
8.07%
Research Firm
1.42%
Individual Investor
0.61%
Bank and Trust
0.03%
Pension Fund
0.01%
Other
12.00%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
239
133.92M
99.37%
+16.61K
2025Q3
241
133.90M
109.10%
+4.79M
2025Q2
226
132.04M
110.14%
-1.07M
2025Q1
214
132.76M
108.57%
-12.24M
2024Q4
180
128.06M
101.80%
+5.92M
2024Q3
158
122.07M
88.34%
+22.15M
2024Q2
135
99.90M
89.43%
+12.17M
2024Q1
129
87.74M
96.45%
-9.01M
2023Q4
114
84.27M
95.12%
+1.65M
2023Q3
113
82.62M
96.02%
+2.24M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Medicxi Ventures (UK) LLP
19.96M
13.67%
--
--
Sep 30, 2025
Avoro Capital Advisors LLC
10.81M
7.4%
+5.81M
+116.16%
Sep 30, 2025
Adage Capital Management, L.P.
10.04M
6.87%
+1.63M
+19.42%
Sep 30, 2025
Index Ventures SA
9.96M
6.82%
--
--
Sep 30, 2025
General Atlantic LLC
7.37M
5.04%
-2.31M
-23.91%
Nov 26, 2025
Fidelity Management & Research Company LLC
6.24M
4.27%
+2.41M
+63.08%
Sep 30, 2025
Janus Henderson Investors
5.41M
3.7%
-1.12M
-17.21%
Sep 30, 2025
T. Rowe Price Associates, Inc.
4.80M
3.29%
-1.10M
-18.69%
Sep 30, 2025
Farallon Capital Management, L.L.C.
4.33M
2.97%
-198.00K
-4.37%
Sep 30, 2025
First Light Asset Management, LLC
3.64M
2.49%
-657.60K
-15.32%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
3.56%
Virtus LifeSci Biotech Clinical Trials ETF
1.4%
Invesco Nasdaq Biotechnology ETF
0.23%
ProShares Ultra Nasdaq Biotechnology
0.23%
T Rowe Price Small-Mid Cap ETF
0.15%
iShares Biotechnology ETF
0.13%
Fidelity Fundamental Small-Mid Cap ETF
0.11%
iShares Intl Small Cap Equity Factor ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
SPDR S&P International Small Cap ETF
0%
View more
iShares Neuroscience and Healthcare ETF
Proportion3.56%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.4%
Invesco Nasdaq Biotechnology ETF
Proportion0.23%
ProShares Ultra Nasdaq Biotechnology
Proportion0.23%
T Rowe Price Small-Mid Cap ETF
Proportion0.15%
iShares Biotechnology ETF
Proportion0.13%
Fidelity Fundamental Small-Mid Cap ETF
Proportion0.11%
iShares Intl Small Cap Equity Factor ETF
Proportion0.01%
Fidelity Nasdaq Composite Index ETF
Proportion0.01%
SPDR S&P International Small Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
